Last reviewed · How we verify
Terazosin (Hytrin)
Terazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.
Terazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia. Used for Benign prostatic hyperplasia, Hypertension.
At a glance
| Generic name | Terazosin (Hytrin) |
|---|---|
| Sponsor | Hospital Authority, Hong Kong |
| Drug class | Alpha-1 adrenergic receptor antagonist |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking alpha-1 adrenergic receptors, terazosin decreases the muscle tone in the prostate and bladder neck, allowing for easier urination. This mechanism is specific to the treatment of benign prostatic hyperplasia and hypertension.
Approved indications
- Benign prostatic hyperplasia
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Orthostatic hypotension
Key clinical trials
- Terazosin And Metabolic Energetics in Parkinson's Disease (PHASE2)
- Terazosin for Dementia With Lewy Bodies (PHASE1, PHASE2)
- Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
- Terazosin and Parkinson's Disease Extension Study (PHASE2)
- Terazosin And Metabolic Engagement in Parkinson's Disease (PHASE1, PHASE2)
- Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
- Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terazosin (Hytrin) CI brief — competitive landscape report
- Terazosin (Hytrin) updates RSS · CI watch RSS
- Hospital Authority, Hong Kong portfolio CI